Despite the availability of current therapeutic approaches, including glucose-lowering agents, such as sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) agonists as well as renin–angiotensin–aldosterone system (RAAS) blockers, there is no cure yet, and a significant number of diabetic subjects progress to end-stage renal disease (ESRD) despite the use of current treatments [4,5,6,7,8]. This evidence concerns the gene GCG and stage 5 chronic kidney disease.